Journal ArticleDOI
Review - Treatment of Helicobacter pylori infection 2020
Reads0
Chats0
TLDR
This review summarizes important studies regarding Helicobacter pylori therapy published from April 2019 to April 2020 that involve studies assessing antibiotic resistance, and there is also growing momentum behind the utility of vonoprazan as an alternative to proton pump inhibitor (PPI) therapy and also bismuth‐based regimens as a first‐line regimen.Abstract:
This review summarizes important studies regarding Helicobacter pylori therapy published from April 2019 to April 2020. The main themes that emerge involve studies assessing antibiotic resistance, and there is also growing momentum behind the utility of vonoprazan as an alternative to proton pump inhibitor (PPI) therapy and also bismuth-based regimens as a first-line regimen. Antibiotic resistance is rising wherever it is being assessed, and clarithromycin resistance in particular has reached a point where it may no longer be a viable therapy without previous testing in many regions of the world. The evidence for the efficacy of a bismuth-based quadruple therapy as a first-line therapy is now very clearly established, and there is substantial evidence that it is the best performing first-line therapy. The utility of vonoprazan as an alternative to PPI therapy, especially in resistant and difficult-to-treat groups, has also been considered in great detail this year, and it may offer an opportunity in the near future to reduce the problem of antibiotic resistance.read more
Citations
More filters
Journal ArticleDOI
40 Years of Helicobacter pylori: A Revolution in Biomedical Thought
TL;DR: The role of the bacterium H. pylori in carcinogenesis has been discovered and demonstrated, and new prospective research is currently attempting to investigate the role of other factors in the stomach and other organs.
Journal ArticleDOI
Selective Inhibition of Helicobacter pylori Carbonic Anhydrases by Carvacrol and Thymol Could Impair Biofilm Production and the Release of Outer Membrane Vesicles.
Rossella Grande,Simone Carradori,Valentina Puca,Irene Vitale,Andrea Angeli,Alessio Nocentini,Alessandro Bonardi,Paola Gratteri,Paola Lanuti,Giuseppina Bologna,Pasquale Simeone,Clemente Capasso,Viviana De Luca,Claudiu T. Supuran +13 more
TL;DR: In this article, the authors assessed the anti-H. pylori activity of thymol and carvacrol in terms of carbonic anhydrases inhibition, isoform selectivity, growth impairment, biofilm production, and release of associated outer membrane vesicles-eDNA.
Journal ArticleDOI
Impact of food-derived bioactive peptides on gut function and health.
Xiaoyu Bao,Jianping Wu +1 more
TL;DR: This review summarizes the available evidence regarding the effects of food-derived bioactive peptides on gut function and health and concludes that dietary peptides positively impact gastrointestinal homeostasis by modulating the barrier function, immune responses, and gut microbiota.
Journal ArticleDOI
Lactobacillus plantarum ZJ316 Attenuates Helicobacter pylori-Induced Gastritis in C57BL/6 Mice.
TL;DR: Zhang et al. as discussed by the authors found that Lactobacillus plantarum ZJ316 had preventive and therapeutic effects on H. pylori-induced gastritis by regulating the gastric microbiota and reducing mucosal inflammation.
Journal ArticleDOI
Antibody-conjugated liposomes loaded with indocyanine green for oral targeted photoacoustic imaging-guided sonodynamic therapy of Helicobacter pylori infection.
TL;DR: In this paper , a monoclonal antibody-conjugated nanoliposome loaded with indocyanine green (ICG) was successfully developed for targeted photoacoustic (PA) imaging-guided sonodynamic therapy (SDT) of H. pylori infection in vivo.
References
More filters
Journal ArticleDOI
Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report
Peter Malfertheiner,Francis Mégraud,Colm O'Morain,Javier P. Gisbert,Ernst J. Kuipers,A. T. R. Axon,Franco Bazzoli,Antonio Gasbarrini,John Atherton,David Y. Graham,Richard H. Hunt,Paul Moayyedi,Theodore Rokkas,Massimo Rugge,Michael Selgrad,Sebastian Suerbaum,Kentaro Sugano,Emad M. El-Omar +17 more
TL;DR: This fifth edition of the Maastricht Consensus Report describes how experts from 24 countries examined new data related to H. pylori infection in the various clinical scenarios and provided recommendations on the basis of the best available evidence and relevance.
Journal ArticleDOI
Helicobacter pylori infection. Implications for ulcer therapy in older patients.
Journal ArticleDOI
Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs.
TL;DR: It appears that the chemical properties of a drug critical to CYP3A4 inactivation include formation of reactive metabolites by CYP isoenzymes, preponderance of CYP inducers and P-glycoprotein (P-gp) substrate, and occurrence of clinically significant pharmacokinetic interactions with coadministered drugs.
Journal ArticleDOI
Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer.
Takahisa Furuta,Kyoichi Ohashi,Takashi Kamata,Misako Takashima,Kazuhiro Kosuge,Tsunehisa Kawasaki,Hiroyuki Hanai,Takahiro Kubota,Takashi Ishizaki,Eizo Kaneko +9 more
TL;DR: Whether differences in CYP2C19 genotype status would affect cure rates for H. pylori infection and peptic ulcer in patients who received dual therapy with omeprazole and amoxicillin is prospectively studied.
Journal ArticleDOI
Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study
TL;DR: Vonoprazan is effective as part of first-line triple therapy and aspart of second- line triple therapy in H pylori-positive patients with a history of gastric or duodenal ulcer.